| BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma |
Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET SAN RAFAEL, Calif. |
prnewswire.com |
2025-05-16 11:30:00 |
Czytaj oryginał (ang.) |
| BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings |
New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits SAN RAFAEL, Calif. , May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from studies of VOXZOGO ® (vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal conditions. |
prnewswire.com |
2025-05-12 13:05:00 |
Czytaj oryginał (ang.) |
| Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-09 14:40:46 |
Czytaj oryginał (ang.) |
| Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-06 14:50:35 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-05 14:55:35 |
Czytaj oryginał (ang.) |
| BioMarin's First-Quarter Earnings & Sales Beat Estimates |
BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025. |
zacks.com |
2025-05-02 18:25:31 |
Czytaj oryginał (ang.) |
| BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-02 00:35:38 |
Czytaj oryginał (ang.) |
| BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript |
BioMarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings Call Transcript |
seekingalpha.com |
2025-05-01 23:25:29 |
Czytaj oryginał (ang.) |
| BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates |
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.71 per share a year ago. |
zacks.com |
2025-05-01 22:20:48 |
Czytaj oryginał (ang.) |
| BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance |
First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif. |
prnewswire.com |
2025-05-01 20:05:00 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-23 14:46:21 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-18 14:45:38 |
Czytaj oryginał (ang.) |
| BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET |
SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025, at 4:30 p.m. |
prnewswire.com |
2025-04-17 13:00:00 |
Czytaj oryginał (ang.) |
| BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q1 Release |
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-16 15:06:07 |
Czytaj oryginał (ang.) |
| 6 Stocks With Clear Price Dislocations That I Purchased During Wall Street's Historic Volatility |
The old idiom "blink, and you'll miss it" might be the best descriptor of the historic volatility we've witnessed on Wall Street over the trailing week, as of this writing on April 9. |
fool.com |
2025-04-11 07:06:00 |
Czytaj oryginał (ang.) |
| Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? |
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-04-10 17:15:45 |
Czytaj oryginał (ang.) |
| Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? |
BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-04-10 13:20:41 |
Czytaj oryginał (ang.) |
| Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On |
Investors looking to maintain exposure to healthcare can invest in large-cap U.S.-based companies like UHS, BMRN and ABT. |
zacks.com |
2025-04-09 20:00:41 |
Czytaj oryginał (ang.) |
| 5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 |
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector. |
zacks.com |
2025-04-07 18:25:39 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) |
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2025-04-07 17:45:33 |
Czytaj oryginał (ang.) |
| BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA |
SAN RAFAEL, Calif. , Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA. |
prnewswire.com |
2025-02-25 11:00:00 |
Czytaj oryginał (ang.) |
| BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors |
SAN RAFAEL, Calif. , Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. |
prnewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why |
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2025-02-24 15:45:34 |
Czytaj oryginał (ang.) |
| Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 40.5% in BioMarin (BMRN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-02-24 12:55:29 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today |
BioMarin Pharmaceutical (BMRN 4.75%) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price, contrasting quite sharply with the 0.4% decline of the S&P 500 index on the day. |
fool.com |
2025-02-20 19:56:00 |
Czytaj oryginał (ang.) |
| BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View |
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027. |
zacks.com |
2025-02-20 12:26:19 |
Czytaj oryginał (ang.) |
| Why Is BioMarin Stock Trading Higher On Thursday? |
On Wednesday, BioMarin Pharmaceutical Inc. BMRN reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. |
benzinga.com |
2025-02-20 11:39:31 |
Czytaj oryginał (ang.) |
| BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript |
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q4 2024 Earnings Conference Call February 19, 2025 4:30 PM ET Company Participants Traci McCarty - Head of IR Alexander Hardy - President and CEO Brian Mueller - EVP and CFO Cristin Hubbard - EVP and Chief Commercial Officer Greg Friberg - EVP and Chief Research & Development Officer Conference Call Participants Philip Nadeau - TD Cowen Jessica Fye - JPMorgan Cory Kasimov - Evercore Christopher Raymond - Piper Sandler Gena Wang - Barclays Julian Pino - Stifel Akash Tewari - Jefferies Eli Merle - UBS Kostas Biliouris - BMO Capital Markets Sadia Rahman - Wells Fargo Olivia Brayer - Cantor Fitzgerald Alex Hammond - Wolfe Research Operator Ladies and gentlemen, thank you for standing by and welcome to the BioMarin Pharmaceuticals fourth quarter and full year 2024 conference call. All lines have been placed on mute to prevent any background noise. |
seekingalpha.com |
2025-02-19 22:08:58 |
Czytaj oryginał (ang.) |
| Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-19 20:31:14 |
Czytaj oryginał (ang.) |
| BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates |
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.49 per share a year ago. |
zacks.com |
2025-02-19 20:20:24 |
Czytaj oryginał (ang.) |
| BioMarin: EPS Surges Past Expectations |
BioMarin Pharmaceutical (BMRN 1.16%), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped analysts' consensus expectations. Adjusted earnings per share (EPS) reached $0.92, significantly outperforming the anticipated $0.53. |
fool.com |
2025-02-19 18:50:03 |
Czytaj oryginał (ang.) |
| BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance |
Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at Constant Currency Y/Y); FY 2024 Total Revenues of $2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif. |
prnewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? |
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week. |
zacks.com |
2025-02-17 12:30:34 |
Czytaj oryginał (ang.) |
| BioMarin to Report Q4 Earnings: Here's What to Expect |
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo. |
zacks.com |
2025-02-17 10:21:07 |
Czytaj oryginał (ang.) |
| Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics |
Get a deeper insight into the potential performance of BioMarin (BMRN) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-02-13 12:16:16 |
Czytaj oryginał (ang.) |
| BMRN vs. CSLLY: Which Stock Is the Better Value Option? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors? |
zacks.com |
2025-02-12 14:41:17 |
Czytaj oryginał (ang.) |
| BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-12 13:06:31 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love BioMarin (BMRN) |
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-02-05 15:45:33 |
Czytaj oryginał (ang.) |
| BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET |
SAN RAFAEL, Calif. , Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m. |
prnewswire.com |
2025-02-05 11:00:00 |
Czytaj oryginał (ang.) |
| 4 Stocks That Sport Impressive Interest Coverage Ratio |
BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships. |
zacks.com |
2025-02-04 12:11:33 |
Czytaj oryginał (ang.) |
| 10 Magnificent Stocks That Can Make You Richer in 2025 |
For a second straight year, investors have been given every reason to smile. As of this writing, with one trading day left in 2024, the iconic Dow Jones Industrial Average, benchmark S&P 500, and growth stock-powered Nasdaq Composite have respectively gained 13%, 24%, and 30%! |
fool.com |
2025-01-03 07:06:00 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) |
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-01-02 15:54:34 |
Czytaj oryginał (ang.) |
| BMRN or TECH: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-01-02 14:46:39 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-26 12:40:23 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-24 12:45:29 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? |
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately. |
zacks.com |
2024-12-19 11:40:33 |
Czytaj oryginał (ang.) |
| BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-11 12:50:16 |
Czytaj oryginał (ang.) |
| Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report? |
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-28 14:36:13 |
Czytaj oryginał (ang.) |
| Can BioMarin Stock Live Up to Wall Street's High Expectations? |
BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. |
marketbeat.com |
2024-11-22 09:01:17 |
Czytaj oryginał (ang.) |
| Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call |
Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acondrophasia, hemophilia and patent expiry issues, making the medium term outlook tricky. Long term, a new management is promising $4bn of revenues by 2027, and long term mid-teen revenue growth. |
seekingalpha.com |
2024-11-21 17:00:40 |
Czytaj oryginał (ang.) |
| Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-21 12:45:41 |
Czytaj oryginał (ang.) |
| Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-20 12:45:24 |
Czytaj oryginał (ang.) |
| BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 |
SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia. |
prnewswire.com |
2024-11-16 12:45:00 |
Czytaj oryginał (ang.) |
| BioMarin to Participate in Three Upcoming Investor Conferences |
UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif. , Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences. |
prnewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-05 12:41:13 |
Czytaj oryginał (ang.) |
| Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" |
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-11-04 15:46:11 |
Czytaj oryginał (ang.) |
| BioMarin (BMRN) Upgraded to Buy: Here's Why |
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-04 15:01:15 |
Czytaj oryginał (ang.) |
| BMRN vs. INCY: Which Stock Is the Better Value Option? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-04 14:46:23 |
Czytaj oryginał (ang.) |
| Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2024-11-04 12:50:24 |
Czytaj oryginał (ang.) |
| BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised |
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance. |
zacks.com |
2024-10-30 14:10:28 |
Czytaj oryginał (ang.) |